Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 1,162 Shares of Company Stock

Key Points

• Natera insider Solomon Moshkevich sold 1,162 shares at an average price of $426.34, totaling $495,407. The sale was conducted under a Rule 10b5-1 plan to cover tax obligations from vested equity awards, reducing his holdings by 1.1%.
• Natera shares rose to $436, near their 52-week high of $437.41, while the company’s latest reported revenue increased 37.7% year over year to $752.75 million and exceeded analysts’ estimates.
• Analysts maintain a generally bullish outlook, with a “Moderate Buy” consensus and an average price target of $394.31, although upcoming third-quarter results and concerns about valuation and potential negative earnings could drive volatility.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 1,162 shares of the company's stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total value of $495,407.08. Following the completion of the transaction, the insider directly owned 104,742 shares in the company, valued at $44,655,704.28. This trade represents a 1.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, October 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $406.00, for a total value of $410,060.00.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $414.22, for a total transaction of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80.

Natera Price Performance

Natera stock traded up $11.58 during trading hours on Thursday, hitting $436.00. The company had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41. The company has a 50-day moving average price of $375.27 and a two-hundred day moving average price of $265.54.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same period last year, the company posted ($0.74) earnings per share. The company's quarterly revenue was up 37.7% compared to the same quarter last year. On average, research analysts forecast that Natera, Inc. will post -1.14 earnings per share for the current year.

Institutional Trading of Natera

A number of institutional investors have recently made changes to their positions in the business. SYM FINANCIAL Corp raised its position in shares of Natera by 1.7% in the 3rd quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company's stock valued at $784,000 after purchasing an additional 32 shares during the last quarter. Versant Capital Management Inc raised its stake in shares of Natera by 4.6% during the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company's stock valued at $337,000 after buying an additional 36 shares during the last quarter. VestGen Advisors LLC lifted its stake in shares of Natera by 3.1% in the 3rd quarter. VestGen Advisors LLC now owns 1,460 shares of the medical research company's stock valued at $603,000 after purchasing an additional 44 shares during the period. Parallel Advisors LLC boosted its stake in shares of Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock worth $181,000 after acquiring an additional 47 shares in the last quarter. Finally, Raiffeisen Bank International AG grew its holdings in Natera by 48.5% in the second quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company's stock valued at $41,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on NTRA shares. TD Cowen lifted their price objective on Natera from $340.00 to $480.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. Evercore reissued an "outperform" rating and set a $300.00 target price on shares of Natera in a research report on Monday, July 6th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $360.00 to $460.00 and gave the company an "overweight" rating in a report on Wednesday, October 14th. UBS Group increased their price objective on shares of Natera from $290.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, September 9th. Finally, Stephens lifted their price objective on shares of Natera from $305.00 to $350.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Natera has an average rating of "Moderate Buy" and an average target price of $394.31.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.